SUNNYVALE, Calif.--(BUSINESS WIRE)--IntraOp Medical Corporation (OTCBB: IOPM), a provider of intraoperative electron-beam radiation therapy (IOERT) solutions for the treatment and eradication of cancer, today announced that the Instituto Nacional de Cancerologia in Bogota, Colombia has begun delivering IOERT breast cancer treatment using the company’s Mobetron linear accelerator.
IntraOp’s Mobetron is a mobile technology that delivers IOERT to a tumor site during cancer surgery. It enables radiation and surgical oncologists to pinpoint the optimal site for radiation and delivers a cancer-eradicating dose during the procedure. Because the Mobetron is a mobile, self-shielded device, doctors are able to move it among operating rooms to treat a greater number of patients more efficiently.
“We are very excited to be the first hospital in Latin America with an operating room-based IOERT program. Breast cancer will certainly be one of the focuses of our IOERT program. IOERT has demonstrated very impressive results in breast cancer therapy, both as a boost treatment at the time of surgery and as a single dose treatment to replace all post-operative external beam radiation treatments. We feel that IOERT will enable us to reduce breast cancer recurrences and offer our patients a better quality of care overall. ” said Dr. Rosa Ospina, Chairman of Radiation Oncology at the institute.
Instituto Nacional de Cancerologia’s early adoption of IOERT is another realization of the institute’s charter to offer leading edge medical treatment utilizing technology from around the world.
During recent years, IOERT has been gaining popularity as an effective radiation treatment in many parts of the world, as recent published studies continue to show its effectiveness in treating breast cancer and other diseases. As a boost dose at the time of surgery, followed by a regular course of radiation treatment, IOERT has been shown to reduce five-year recurrence rates for breast cancer by more than a factor of four. Reduced recurrence correlates directly with increased patient survival.
As a single-dose treatment in select women, IOERT has demonstrated equivalent effectiveness to the traditional regimen of post-operative radiation. IOERT can eliminate the need for a six week course of radiation treatment and increases overall quality-of-life. Moreover, it may help make the benefits of radiation treatment a reality for rural populations without radiation therapy centers in commuting distance.
“We are excited to play a role in bringing an advanced IOERT program to Latin America through installation of the Mobetron at Instituto Nacional de Cancerologia,” said John Powers, CEO for IntraOp Medical. “As more countries focus on evidence-based medicine, we are seeing a dramatic expansion of interest in IOERT as a standard treatment at centers around the world. These centers recognize the clear clinical benefits to their patients of targeting cancer cells directly at the time of surgery. Breast IOERT is rapidly becoming accepted as a standard method to increase radiation therapy precision, conserve breast tissue and enhance long-term survival rates.”
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively – for all cancer patients. The company’s flagship product, the Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use the Mobetron as a vital part of their comprehensive cancer program.
For more information about IntraOp Medical and the Mobetron, please visit: www.intraopmedical.com